Bio-Techne has worked tirelessly for the past year to enable our customers to research, characterize, and develop therapies against the novel SARS-CoV-2 virus. Efforts have produced a wide portfolio of important reagents and analytical tools. In this technical talk, Dr. Heger discusses how we leveraged our own SARS-CoV-2 recombinant proteins and antibodies to rapidly generate fast, reproducible, and sensitive assays on our Simple Western and Simple Plex platforms to characterize the immune response in COVID-19.
Speakers
|
|
Dr. Chris Heger Director of Applications Science Analytical Solutions Division of Bio-Techne
|
Dr. Chris Heger, Director of Applications Science for the Analytical Solutions Division of Bio-Techne, received his doctoral degree in Pharmacology from Cornell University and completed his post-doctoral training at the National Cancer Institute in Antibody Development, Purification and Technology Evaluation. Chris joined Protein Simple in 2011, starting as a Field Applications Scientist, and subsequently further building the East Coast support team as Field Manager. During these years, Chris a developed broad but deep understanding of the instrumentation and their application across diverse research areas. In 2016, Chris moved to California to lead the Applications Science group, chartered with creating scientific collateral, fostering collaborations, training, and application development. Chris is an expert in immunoassays, capillary electrophoresis, protein and antibody purification, and chromatography.
|
|